Όνομα προϊόντος	Flibanserin
Other Name	Addyi, Bimt; BIMT17BS; Flibanserin(BIMT17)
Original	Κίνα
CAS	167933-07-5
Μοριακός τύπος	C20H21F3N4O
MW	390.4
Καθαρότητα	98% ελάχ.
Εμφάνιση	Λευκή σκόνη
Πιστοποίηση	SGS, ISO 9001, KOSHER
Χρήση	A kind of drug being studied as a treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD).
Μοριακή δομή

Περιγραφή:

Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three.The certainty of the estimate is low.The side effects of dizziness, sleepiness, and nausea occur about three to four times more often. Flibanserin is a drug developed to treat hypoactive sexual desire disorder (HSDD) in women. Women with HSDD have a chronic lack of interest in sex that cannot be explained by another medical condition. HSDD is also accompanied by feelings of distress. Sometimes, flibanserin is called the “female Viagra,” but that term isn’t quite accurate. Viagra is a drug used to treat erectile dysfunction in men and works by improving blood flow to the penis. Με άλλα λόγια, it mainly works on the genitals. Flibanserin is different because it works on a woman’s brain. The brain is often considered a woman’s more important sexual organ. Much of her sexual response cycle originates in her brain.

Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin’s mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Flibanserin is being hailed as “Viagras for women.” The experimental drug – designed for post-menopausal women with low sex drives – has now won approval from an advisory panel for the Food and Drug Administration (FDA).

Flibanserin is an antidepressant that failed to help depression in clinical trials, but was noted to have improved sexual health outcomes. It’s not uncommon for a drug to be developed for one purpose, then approved for another. Sildenafill was originally developed to lower blood pressure, but failed those trials. The benefit of both of these drugs was discovered by accident. Ωστόσο, flibanserin has now been studied for its effects on sexual health for nearly a decade. Flibanserin doesn’t have any interactions with hormonal medications, Thorp says. It does seem to interact with the original libido helper, though: some panelists recommended a warning against drinking alcohol while taking it, Reuters reported. (Interested in natural alternatives to hormone replacement therapy? The Natural Menopause Solution has everything you need to tame symptoms and trigger rapid, healthy weight loss in menopausal women. Flibanserin (INN, USAN), sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).The medication increases the number of satisfying sexual events per month by about one half to one over placebo from a starting point of about two to three. Flibanserin ( Addyi ) is a new drug being investigated for the prevention of HSDD in woman. HSDD, is a relatively new term developed to describe Hypoactive Sexual Desire Disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. Studies show that about 10-20% of women face this problem and some say HSDD outnumbers men with sexual problems. Flibanserin is classified as a 5-HT serotonin receptor agonist and a dopamine D4 receptor partial agonist. It is a Non-Hormonal agent that in essence increases dopamine and noradrenalin while reducing Serotonin in the brain. This in return seemingly has a positive effect on a woman’s sexual craving who was otherwise lacking in this area. The benefits of it being Non-Hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues.